Ab-Interno Canaloplasty In Patients With Primary Angle Closure – 12-Month Outcomes
Published 2022
- 40th Congress of the ESCRS
Reference: FPM04.12
| Type: Free paper
| DOI:
10.82333/0z3s-b319
Authors:
Mahmoud Khaimi* 1
, Kai Ding 2
1Dean McGee Eye Institute - Oklahoma Health Center,Oklahoma City,United States, 2Department of Biostatistics and Epidemiology,University of Oklahoma Health Sciences Center,Oklahoma City,United States
Purpose
To investigate the clinical outcomes of ab-interno canaloplasty (ABiC) with iTrack microcatheter (Nova Eye Medical, Fremont, USA) performed as a standalone procedure (ABiC) and in combination with phacoemulsification (ABiC+phaco) in patients with narrow-angle glaucoma (NAG) or chronic angle-closed glaucoma (CACG).
Setting
Dean McGee Eye Institute/University of Oklahoma in Oklahoma City
Methods
A single center, retrospective case series of eyes undergoing ABiC with a diagnosis of NAG or CACG based on gonioscopy findings. Patients were excluded if they had undergone a glaucoma procedure previously except for laser SLT or CPC. Outcome measures include intraocular pressure (IOP) and number of glaucoma medications.
Results
Twenty-nine eyes (5 ABiC and 24 ABiC+phaco) were eligible for inclusion. Mean baseline IOP was 25.4±6.7mmHg (ABiC) and 20.5±8.2 mmHg (ABiC+phaco) and glaucoma medication number was 2.2±1.8 (ABiC) and 1.8±1.5 (ABiC+phaco), with no significant difference among the groups (P=0.2;0.6) At 12 months IOP was reduced to 15.3±2.2mmHg (n=4) and 13.8±3.7mmHg (n=13) respectively and mean number of medications were reduced to 0.5±0.6 and 0.3±0.6 respectively, with no significant difference among the groups (p=0.4;0.7). No serious intra-operative or postoperative complications were reported.
Conclusions
ABiC, performed as standalone or combined with phacoemulsification, is a safe and clinically effective treatment in angle closure and narrow-angle glaucoma patients up to 12 months.